Mechanically, TRIM16 could promote NFKBIZ ubiquitination to exacerbate HCC progression, which may be the underlying mechanism of the occurrence of sorafenib insensitivity in HCC clinical treatment (Fig. 8F). Here, NFKBIZ is linked to hepatocellular carcinoma.